Evidence map›Paper›PMID 35409819›Full record

ArticleInternational journal of environmental research and public health2022

Cardiovascular Outcomes among Combustible-Tobacco and Electronic Nicotine Delivery System (ENDS) Users in Waves 1 through 5 of the Population Assessment of Tobacco and Health (PATH) Study, 2013-2019.

Martin C Mahoney, Cheryl Rivard, Heather L Kimmel, Hoda T Hammad, Eva Sharma, Michael J Halenar, Jim Sargent, K Michael Cummings, Ray Niaura, Maciej L Goniewicz and 12 more

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 2 countries.

Martin C MahoneyRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0002-5069-1140
Cheryl RivardRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0002-0179-1495
Heather L KimmelNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MS 20892, USA.ORCID 0000-0001-8278-0095
Hoda T HammadCenter for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Eva SharmaWestat, Rockville, MD 20850, USA.
Michael J HalenarWestat, Rockville, MD 20850, USA.ORCID 0000-0002-8703-3811
Jim SargentThe C. Everette Koop Institute at Dartmouth, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
K Michael CummingsMedical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-7103-7017
Ray NiauraNYU School of Global Public Health, New York, NY 10003, USA.ORCID 0000-0002-0856-3540
Maciej L GoniewiczRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0001-6748-3068
Maansi Bansal-TraversRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Dorothy HatsukamiUniversity of Minnesota, Minneapolis, MN 55414, USA.
Diann GaalemaUniversity of Vermont, Burlington, VT 05404, USA.
Geoffrey FongUniversity of Waterloo, Waterloo, ON N2L 3G1, Canada.
Shannon GravelyUniversity of Waterloo, Waterloo, ON N2L 3G1, Canada.ORCID 0000-0001-5224-9105
Carol H ChristensenCenter for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Ryan HaskinsCenter for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Marushka L SilveiraNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MS 20892, USA.
Carlos BlancoNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MS 20892, USA.
Wilson ComptonNational Institute on Drug Abuse, National Institutes of Health, Bethesda, MS 20892, USA.ORCID 0000-0003-3108-5118
Cassandra A StantonWestat, Rockville, MD 20850, USA.
Andrew HylandRoswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Roswell Park Comprehensive Cancer Center · USNational Institutes of Health · USUnited States Food and Drug Administration · USWestat (United States) · USUniversity of Waterloo · CAMedical University of South Carolina · USUniversity of Minnesota · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior studies have not clearly established risk of cardiovascular disease (CVD) among smokers who switch to exclusive use of electronic nicotine delivery systems (ENDS). We compared cardiovascular disease incidence in combustible-tobacco users, those who transitioned to ENDS use, and those who quit tobacco with never tobacco users.

methodsThis prospective cohort study analyzes five waves of Population Assessment of Tobacco and Health (PATH) Study data, Wave 1 (2013-2014) through Wave 5 (2018-2019). Cardiovascular disease (CVD) incidence was captured over three intervals (Waves 1 to 3, Waves 2 to 4, and Waves 3 to 5). Participants were adults (40+ years old) without a history of CVD for the first two waves of any interval. Change in tobacco use status, from exclusive past 30 day use of any combustible-tobacco product to either exclusive past 30 day ENDS use, dual past 30 day use of ENDS and combustible-tobacco, or no past 30 day use of any tobacco, between the first two waves of an interval was used to predict onset of CVD between the second and third waves in the interval. CVD incidence was defined as a new self-report of being told by a health professional that they had congestive heart failure, stroke, or a myocardial infarction. Generalized estimating equation (GEE) analyses combined 10,548 observations across intervals from 7820 eligible respondents.

resultsOverall, there were 191 observations of CVD among 10,548 total observations (1.7%, standard error (SE) = 0.2), with 40 among 3014 never users of tobacco (1.5%, SE = 0.3). In multivariable models, CVD incidence was not significantly different for any tobacco user groups compared to never users. There were 126 observations of CVD among 6263 continuing exclusive combustible-tobacco users (adjusted odds ratio [AOR] = 1.44; 95% confidence interval (CI) 0.87-2.39), 15 observations of CVD among 565 who transitioned to dual use (AOR = 1.85; 0.78-4.37), and 10 observations of CVD among 654 who quit using tobacco (AOR = 1.18; 0.33-4.26). There were no observations of CVD among 53 who transitioned to exclusive ENDS use.

conclusionsThis study found no difference in CVD incidence by tobacco status over three 3 year intervals, even for tobacco quitters. It is possible that additional waves of PATH Study data, combined with information from other large longitudinal cohorts with careful tracking of ENDS use patterns may help to further clarify this relationship.

Indexed as

Cardiovascular DiseasesElectronic Nicotine Delivery SystemsTobacco ProductsAdultHumansProspective Studiescardiovascular diseaseelectronic cigaretteelectronic nicotine delivery systems (ENDS)health surveytobacco use

Identifiers

PMID35409819
PMCPMC8998731
OpenAlexW4221013247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.